Literature DB >> 10871817

Urinary albumin excretion and transcapillary escape rate of albumin in malignancies.

L M Pedersen1, L Terslev, P G SŁrensen, K H Stokholm.   

Abstract

Transcapillary escape rate of albumin was determined in 22 patients with different malignancies. In addition, urinary albumin excretion rate was measured in 24-h urine samples using a sensitive immunoassay. Increased urinary albumin excretion was defined as >/=20 microg/min according to conventional standards. Renal glomerular filtration and tubular function was estimated by 51Cr-EDTA plasma clearance and urinary beta 2-microglobulin, respectively. Median urinary albumin excretion rate was 15.0 microg/min (range 6-510 microg/min) and the frequency of increased urinary albumin excretion was 41%. This agrees with other studies showing increased albuminuria in several types of malignant diseases. Patients with advanced disease (tumour, node, metastasis (TNM) stage II-IV) had a significantly higher urinary albumin excretion rate than patients with localized disease (TNM stage I). Serum creatinine, glomerular filtration rate and urinary beta 2-microglobulin were all within normal limits. Median transcapillary escape rate of albumin was 5.5 %/h (range 2-8 %/h) and this level is comparable with values in healthy subjects. There was no significant difference in transcapillary escape rate between patients with elevated urinary albumin excretion and the normoalbuminuric group. Median value of the absolut outflux of albumin was 10.6 g/h with similar levels in patients with increased urinary albumin excretion and patients with normoalbuminuria. Our results indicate a high prevalence of minor glomerular dysfunction with a slightly elevated urinary albumin excretion in patients with malignancies. The normal endothelial function, as estimated by the transcapillary escape rate of albumin, suggests an overall unaffected capillary permeability and increased urinary albumin loss appears to be an isolated renal phenomenon in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871817     DOI: 10.1007/bf02796206

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

1.  Evidence for capillary leakage during chemotherapy in man.

Authors:  E G de Vries; H Beekhuis; R de Jong; N H Mulder; D A Piers
Journal:  Eur J Clin Invest       Date:  1986-06       Impact factor: 4.686

2.  Editorial: Filtration as the main mechanism of overall transcapillary protein escape from the plasma.

Authors:  N A Lassen; H H Parving; N Rossing
Journal:  Microvasc Res       Date:  1974-05       Impact factor: 3.514

3.  Features of endothelial dysfunction in early diabetic nephropathy.

Authors:  T Jensen; J Bjerre-Knudsen; B Feldt-Rasmussen; T Deckert
Journal:  Lancet       Date:  1989-03-04       Impact factor: 79.321

4.  Microalbuminuria in patients with lung cancer.

Authors:  L M Pedersen; N Milman
Journal:  Eur J Cancer       Date:  1998-01       Impact factor: 9.162

5.  Prevalence, concentration, and prognostic importance of proteinuria in patients with malignancies.

Authors:  N Sawyer; J Wadsworth; M Wijnen; R Gabriel
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-07

6.  Urinary albumin excretion in a population based sample of 1011 middle aged non-diabetic subjects. The Copenhagen City Heart Study Group.

Authors:  J S Jensen; B Feldt-Rasmussen; K Borch-Johnsen; G Jensen
Journal:  Scand J Clin Lab Invest       Date:  1993-12       Impact factor: 1.713

7.  Increased transcapillary escape rate of albumin and IgG in essential hypertension.

Authors:  H H Parving; H A Jensen; M Westrup
Journal:  Scand J Clin Lab Invest       Date:  1977-05       Impact factor: 1.713

Review 8.  Cancer and the kidney: complications of neoplasms.

Authors:  M F Fer; T D McKinney; R L Richardson; K R Hande; R K Oldham; F A Greco
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

Review 9.  Screening for microalbuminuria: which measurement?

Authors:  S M Marshall
Journal:  Diabet Med       Date:  1991-10       Impact factor: 4.359

View more
  3 in total

Review 1.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

2.  Association of albuminuria and cancer incidence.

Authors:  Lone Jørgensen; Ivar Heuch; Trond Jenssen; Bjarne K Jacobsen
Journal:  J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 10.121

3.  Proteinuria as a risk factor for mortality in patients with colorectal cancer.

Authors:  Min Jee Kim; Yong Un Kang; Chang Seong Kim; Joon Seok Choi; Eun Hui Bae; Seong Kwon Ma; Sun-Seog Kweon; Soo Wan Kim
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.